Ana Fuentes

1.1k citations
37 papers · 480 indexed · h-index 10
Topics
SARS-CoV-2 and COVID-19 Research (10 papers)Hepatitis C virus research (10 papers)COVID-19 Clinical Research Studies (9 papers)
Partner nations
SpainUnited StatesMexico

In The Last Decade

Ana Fuentes

33 papers receiving 468 citations

Peers

Ana Fuentes
Comparison fields: 5 of 72
  • Epidemiology 191
  • Hepatology 178
  • Infectious Diseases 176
  • Microbiology 139
  • Molecular Biology 55
Replace Ali Ağaçfidan with:
Ali Ağaçfidan Türkiye
Nazha Abughali United States
Roberto Gulminetti Italy
Selma Gökahmetoğlu Türkiye
Anıl Tapısız Türkiye
Adolfo de Salazar Spain
Sinaye Ngcapu South Africa
Thomas Nevin United States
P Gioannini Italy
Ui Yoon Choi South Korea
Ana Fuentes relative to Ali Ağaçfidan Türkiye Ali Ağaçfidan's profile →
Citations per field
00.5×4.0×
Ali Ağaçfidan · 1×
Citations per year

Countries citing papers authored by Ana Fuentes

Since Specialization
Citations

This map shows the geographic impact of Ana Fuentes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Fuentes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Fuentes more than expected).

Fields of papers citing papers by Ana Fuentes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Fuentes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Fuentes. The network helps show where Ana Fuentes may publish in the future.

Co-authorship network of co-authors of Ana Fuentes

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Fuentes. A scholar is included among the top collaborators of Ana Fuentes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Fuentes. Ana Fuentes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 2
4 1
5 0
6 2
7 1
8 2
9 5
10 9
11 81
12 22
13 2
14 5
15 4
16 7
17 3
18 17
19 19
20 22

About Ana Fuentes

Ana Fuentes is a scholar working on Hepatology, Infectious Diseases and Microbiology, having authored 37 papers that have together received 480 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (10 papers), Hepatitis C virus research (10 papers) and COVID-19 Clinical Research Studies (9 papers). The work is most often cited by research in Microbiology (139 citations), Hepatology (178 citations) and Infectious Diseases (176 citations). Ana Fuentes has collaborated with scholars based in Spain, United States and Mexico. Frequent co-authors include Féderico García, Adolfo de Salazar, Antonio Barrientos‐Durán, Julio Plaza‐Díaz, Juan A. Pineda, Antonio Rivero‐Juárez, Antonio Rivero, Mario Frías, Ana Belén Pérez and Gabriel Reina. Their work appears in journals such as PLoS ONE, International Journal of Molecular Sciences and Journal of Clinical Microbiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026